Walter Hasibeder
Research Subjects
Walter Hasibeder has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
A. Mayr
6 shared publications- Hans Knotzer
Department of Anaesthesiology and Critical Care Medicine
5 shared publications - Hanno Ulmer
Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, Innsbruck 6020, Austria
4 shared publications N. Mutz
Division of General and Surgical Intensive Care Medicine, Department of Anesthesia and Critical Care Medicine, The Leopold Franzens University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
4 shared publications- Wolfgang Schobersberger
Universitätsklinik für Anästhesie und Intensivmedizin
4 shared publications B. Friesenecker
3 shared publications
Latest Publications
- 12 April 2010
- Vol. 76 (11) , 905-12
Plasma copeptin levels before and during exogenous arginine vasopressin infusion in patients with advanced vasodilatory shock.
Plasma copeptin levels before and during exogenous arginine vasopressin infusion (AVP) were evaluated, and the value of copeptin levels before AVP therapy to predict complications during AVP therapy and outcome in vasodilatory shock patients was determined. This prospective, observational study was nested in a randomized, controlled trial investigating the effects of two AVP doses (0.033 vs. 0.067 IU/min) on the hemodynamic response in patients with advanced vasodilatory shock due to sepsis, systemic inflammatory response syndrome or after cardiac surgery. Clinical data, plasma copeptin levels and adverse events were recorded before, 24 hours after and 48 hours after randomization. Plasma copeptin levels were elevated before AVP therapy. During AVP, copeptin levels decreased (P<0.001) in both groups (P=0.73). Copeptin levels at randomization predicted the occurrence of ischemic skin lesions (AUC ROC, 0.73; P=0.04), a fall in platelet count (AUC ROC, 0.75; P=0.01) during AVP and intensive care unit mortality (AUC ROC, 0.67; P=0.04). Twenty-five patients (64.1%) exhibited a decrease in copeptin levels. Patients experiencing a decrease in copeptin levels were older (P=0.04), had a higher Sequential Organ Failure Assessment score count before (P=0.03) and during AVP therapy (P=0.04), had a longer intensive care unit stay (P<0.001) and required AVP therapy longer (P=0.008) than patients without a decrease in copeptin levels during AVP. Plasma copeptin levels are elevated in patients with advanced vasodilatory shock. During exogenous AVP therapy, copeptin levels decrease, suggesting suppression of the endogenous AVP system.
- 12 April 2010
- Vol. 76 (11) , 905-12
Plasma copeptin levels before and during exogenous arginine vasopressin infusion in patients with advanced vasodilatory shock.
Plasma copeptin levels before and during exogenous arginine vasopressin infusion (AVP) were evaluated, and the value of copeptin levels before AVP therapy to predict complications during AVP therapy and outcome in vasodilatory shock patients was determined. This prospective, observational study was nested in a randomized, controlled trial investigating the effects of two AVP doses (0.033 vs. 0.067 IU/min) on the hemodynamic response in patients with advanced vasodilatory shock due to sepsis, systemic inflammatory response syndrome or after cardiac surgery. Clinical data, plasma copeptin levels and adverse events were recorded before, 24 hours after and 48 hours after randomization. Plasma copeptin levels were elevated before AVP therapy. During AVP, copeptin levels decreased (P<0.001) in both groups (P=0.73). Copeptin levels at randomization predicted the occurrence of ischemic skin lesions (AUC ROC, 0.73; P=0.04), a fall in platelet count (AUC ROC, 0.75; P=0.01) during AVP and intensive care unit mortality (AUC ROC, 0.67; P=0.04). Twenty-five patients (64.1%) exhibited a decrease in copeptin levels. Patients experiencing a decrease in copeptin levels were older (P=0.04), had a higher Sequential Organ Failure Assessment score count before (P=0.03) and during AVP therapy (P=0.04), had a longer intensive care unit stay (P<0.001) and required AVP therapy longer (P=0.008) than patients without a decrease in copeptin levels during AVP. Plasma copeptin levels are elevated in patients with advanced vasodilatory shock. During exogenous AVP therapy, copeptin levels decrease, suggesting suppression of the endogenous AVP system.
- 1 August 2004
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 48 (7) , 814-819
Arginine vasopressin and serum nitrite/nitrate concentrations in advanced vasodilatory shock
Arginine-vasopressin (AVP) can successfully stabilize hemodynamics in patients with advanced vasodilatory shock. It has been suggested that inhibition of cytokine-induced nitric oxide production may be an important mechanism underlying AVP-induced vasoconstriction. Therefore, serum concentrations of nitrite/nitrate (NOx), the stable metabolite of nitric oxide, were measured in patients suffering from advanced vasodilatory shock treated with either AVP in combination with norepinephrine (NE) or NE alone. This trial was a separate study arm of a previously published prospective, randomized, controlled study on the effects of AVP in advanced vasodilatory shock. Thirty-eight patients were prospectively randomized to receive a combined infusion of AVP (4 U h(-1)) and NE, or NE infusion alone. Serum NOx concentrations were measured at baseline, 24, and 48 h after randomization. The increase in mean arterial pressure during the first hour after study enrollment was documented in all patients. No difference in NOx concentrations was found between groups throughout the study period. AVP patients demonstrated a significantly greater increase in mean arterial pressure than NE patients (22 +/- 10 vs. 5 +/- 9 mmHg; P < 0.001). The magnitude of pressure response to AVP was not correlated with NOx concentrations before start of AVP infusion (Pearson's correlation coefficient, -.009; P = 0.971). Cardiovascular effects of AVP infusion in advanced vasodilatory shock are not mediated by a clinically relevant reduction in serum NOx concentrations. Therefore, hemodynamic improvement of patients in advanced vasodilatory shock during continuous infusion of AVP has to be attributed to other mechanisms than inhibition of nitric oxide synthase. In addition, the magnitude of pressure response to AVP is not correlated with baseline concentrations of NOx.
- 1 August 2004
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 48 (7) , 814-819
Arginine vasopressin and serum nitrite/nitrate concentrations in advanced vasodilatory shock
Arginine-vasopressin (AVP) can successfully stabilize hemodynamics in patients with advanced vasodilatory shock. It has been suggested that inhibition of cytokine-induced nitric oxide production may be an important mechanism underlying AVP-induced vasoconstriction. Therefore, serum concentrations of nitrite/nitrate (NOx), the stable metabolite of nitric oxide, were measured in patients suffering from advanced vasodilatory shock treated with either AVP in combination with norepinephrine (NE) or NE alone. This trial was a separate study arm of a previously published prospective, randomized, controlled study on the effects of AVP in advanced vasodilatory shock. Thirty-eight patients were prospectively randomized to receive a combined infusion of AVP (4 U h(-1)) and NE, or NE infusion alone. Serum NOx concentrations were measured at baseline, 24, and 48 h after randomization. The increase in mean arterial pressure during the first hour after study enrollment was documented in all patients. No difference in NOx concentrations was found between groups throughout the study period. AVP patients demonstrated a significantly greater increase in mean arterial pressure than NE patients (22 +/- 10 vs. 5 +/- 9 mmHg; P < 0.001). The magnitude of pressure response to AVP was not correlated with NOx concentrations before start of AVP infusion (Pearson's correlation coefficient, -.009; P = 0.971). Cardiovascular effects of AVP infusion in advanced vasodilatory shock are not mediated by a clinically relevant reduction in serum NOx concentrations. Therefore, hemodynamic improvement of patients in advanced vasodilatory shock during continuous infusion of AVP has to be attributed to other mechanisms than inhibition of nitric oxide synthase. In addition, the magnitude of pressure response to AVP is not correlated with baseline concentrations of NOx.
- 24 April 2003
- Published by Georg Thieme Verlag KG in AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie
- Vol. 38 (5) , 333-340
Beinaheertrinken: Epidemiologie - Pathophysiologie - Therapie
Ertrinkungsunfälle sind häufige und meist vermeidbare Ereignisse, die oft junge gesunde Menschen betreffen, und mit erheblicher Morbidität und Mortalität einhergehen. Während der Begriff „Ertrinken” den Tod durch Einatmen von Flüssigkeiten bezeichnet, versteht man unter „Beinaheertrinken”, unabhängig vom Vorhandensein einer Flüssigkeitsaspiration, einen Ertrinkungsunfall der zumindest für 24 Stunden überlebt wird. Beinaheertrinken geht mit komplexen pathophysiologischen Störungen einher, die alle Organsysteme betreffen können. Bei der Mehrzahl der Patienten führt Flüssigkeitsaspiration zu einem rasch auftretenden, schweren Lungenversagen mit generalisierter Hypoxie und Sekundärschädigung aller anderen Organsysteme. Entscheidend für die Prognose des Patienten sind letztlich die Schäden am Zentralnervensystem. Aus diesem Grund stellt bereits am Notfallort die sofortige Unterbrechung von Hypoxie und Wiederherstellung stabiler Kreislaufverhältnisse wichtigstes Ziel der Behandlung beinaheertrunkener Patienten dar. Leider gibt es keine zuverlässigen Prognosekriterien, die bereits in der Initialphase der Erkrankung verlässlich Auskunft über das weitere Schicksal des Patienten geben könnten. Zudem zeigen zahlreiche Untersuchungen, dass die Prognose Beinaheertrunkener selbst bei längerer Asphyxie vor allem in kalten Gewässern durchaus gut sein kann. Aus diesem Grund ist ein aggressives therapeutisches Vorgehen mit Einsatz aller zur Verfügung stehenden Techniken bei Beinaheertrunkenen in den meisten Fällen gerechtfertigt. Near-drowning is a frequent preventable accident with a significant morbidity and mortality in a previous healthy population. In most patients the primary injury is pulmonary failure due to fluid aspiration, resulting in severe arterial hypoxemia and secondary damage to other organs. Immediate interruption of hypoxia is of utmost importance in the emergency situation. Accurate neurologic prognosis cannot be predicted from initial clinical presentation, laboratory, radiological or electrophysiological examinations. Prompt resuscitation and aggressive respiratory and cardiovascular treatment are crucial for optimal survival. This review provides the reader with detailed information on epidemiology, pathophysiology, emergency decision making and general treatment in near drowning accidents.
- 24 April 2003
- Published by Georg Thieme Verlag KG in AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie
- Vol. 38 (5) , 333-340
Beinaheertrinken: Epidemiologie - Pathophysiologie - Therapie
Ertrinkungsunfälle sind häufige und meist vermeidbare Ereignisse, die oft junge gesunde Menschen betreffen, und mit erheblicher Morbidität und Mortalität einhergehen. Während der Begriff „Ertrinken” den Tod durch Einatmen von Flüssigkeiten bezeichnet, versteht man unter „Beinaheertrinken”, unabhängig vom Vorhandensein einer Flüssigkeitsaspiration, einen Ertrinkungsunfall der zumindest für 24 Stunden überlebt wird. Beinaheertrinken geht mit komplexen pathophysiologischen Störungen einher, die alle Organsysteme betreffen können. Bei der Mehrzahl der Patienten führt Flüssigkeitsaspiration zu einem rasch auftretenden, schweren Lungenversagen mit generalisierter Hypoxie und Sekundärschädigung aller anderen Organsysteme. Entscheidend für die Prognose des Patienten sind letztlich die Schäden am Zentralnervensystem. Aus diesem Grund stellt bereits am Notfallort die sofortige Unterbrechung von Hypoxie und Wiederherstellung stabiler Kreislaufverhältnisse wichtigstes Ziel der Behandlung beinaheertrunkener Patienten dar. Leider gibt es keine zuverlässigen Prognosekriterien, die bereits in der Initialphase der Erkrankung verlässlich Auskunft über das weitere Schicksal des Patienten geben könnten. Zudem zeigen zahlreiche Untersuchungen, dass die Prognose Beinaheertrunkener selbst bei längerer Asphyxie vor allem in kalten Gewässern durchaus gut sein kann. Aus diesem Grund ist ein aggressives therapeutisches Vorgehen mit Einsatz aller zur Verfügung stehenden Techniken bei Beinaheertrunkenen in den meisten Fällen gerechtfertigt. Near-drowning is a frequent preventable accident with a significant morbidity and mortality in a previous healthy population. In most patients the primary injury is pulmonary failure due to fluid aspiration, resulting in severe arterial hypoxemia and secondary damage to other organs. Immediate interruption of hypoxia is of utmost importance in the emergency situation. Accurate neurologic prognosis cannot be predicted from initial clinical presentation, laboratory, radiological or electrophysiological examinations. Prompt resuscitation and aggressive respiratory and cardiovascular treatment are crucial for optimal survival. This review provides the reader with detailed information on epidemiology, pathophysiology, emergency decision making and general treatment in near drowning accidents.
- 1 April 2003
- Published by Wolters Kluwer Health in Current Opinion in Anaesthesiology
- Vol. 16 (2) , 139-145
Drowning
To summarize current knowledge on pathophysiology and treatment of drowning accidents. Studies and case reports were searched using the keywords drowning, near-drowning, asphyxia, hypoxia and hypothermia in conjunction with organ systems and specific treatment options. Drowning is defined as death by suffocation in a liquid. In contrast, near-drowning is defined as survival beyond 24 h after a drowning accident. Drowning is a frequent preventable accident with a significant morbidity and mortality in a mostly healthy population. In the majority of patients the primary injury is pulmonary, resulting in severe arterial hypoxemia and secondary damage to other organs. Damage to the central nervous system is most critical in terms of patient survival and subsequent quality of life. Therefore, prompt resuscitation and aggressive respiratory and cardiovascular treatment are crucial for optimal survival. Immediate interruption of hypoxia, aggressive treatment of hypothermia and cardiovascular failure are the cornerstones of correct medical treatment. Unfortunately, accurate neurologic prognosis cannot be predicted from initial clinical presentation, laboratory, radiological or electrophysiological examinations. Several case studies have convincingly demonstrated that drowning victims may survive neurologically intact even after prolonged submersion times, in particular in cold water. Therefore, aggressive initial therapeutic efforts are indicated in most near-drowning victims.
- 1 April 2003
- Published by Wolters Kluwer Health in Current Opinion in Anaesthesiology
- Vol. 16 (2) , 139-145
Drowning
To summarize current knowledge on pathophysiology and treatment of drowning accidents. Studies and case reports were searched using the keywords drowning, near-drowning, asphyxia, hypoxia and hypothermia in conjunction with organ systems and specific treatment options. Drowning is defined as death by suffocation in a liquid. In contrast, near-drowning is defined as survival beyond 24 h after a drowning accident. Drowning is a frequent preventable accident with a significant morbidity and mortality in a mostly healthy population. In the majority of patients the primary injury is pulmonary, resulting in severe arterial hypoxemia and secondary damage to other organs. Damage to the central nervous system is most critical in terms of patient survival and subsequent quality of life. Therefore, prompt resuscitation and aggressive respiratory and cardiovascular treatment are crucial for optimal survival. Immediate interruption of hypoxia, aggressive treatment of hypothermia and cardiovascular failure are the cornerstones of correct medical treatment. Unfortunately, accurate neurologic prognosis cannot be predicted from initial clinical presentation, laboratory, radiological or electrophysiological examinations. Several case studies have convincingly demonstrated that drowning victims may survive neurologically intact even after prolonged submersion times, in particular in cold water. Therefore, aggressive initial therapeutic efforts are indicated in most near-drowning victims.
- 1 January 2003
- Published by Springer Nature in Drugs
- Vol. 63 (3) , 237-256
Management of Vasodilatory Shock
The rationale for an arginine vasopressin (argipressin) infusion was put forward after it was discovered that patients in shock states might have an endogenous arginine vasopressin deficiency. Subsequently, several investigations impressively demonstrated that arginine vasopressin can successfully stabilise haemodynamics even in advanced vasodilatory shock. We report on physiological and pharmacological aspects of arginine vasopressin, and summarise current clinical knowledge on employing a continuous arginine vasopressin infusion in critically ill patients with catecholamine-resistant vasodilatory shock of different aetiologies. In view of presented experimental evidence and current clinical experience, a continuous arginine vasopressin infusion of ∼2 to ∼6 IU/h can be considered as a supplemental strategy to vasopressor catecholamines in order to preserve cardiocirculatory homeostasis in patients with advanced vasodilatory shock. Because data on adverse effects are still limited, arginine vasopressin should be reserved for patients in whom adequate haemodynamic stabilisation cannot be achieved with conventional vasopressor therapy or who have obvious adverse effects of catecholamines that result in further significant haemodynamic deterioration. For the same reasons, arginine vasopressin should not be used as a single, alternative vasopressor agent instead of catecholamine vasopressors. Future prospective studies will be necessary to define the exact role of arginine vasopressin in the therapy of vasodilatory shock.
- 1 January 2003
- Published by Springer Nature in Drugs
- Vol. 63 (3) , 237-256
Management of Vasodilatory Shock
The rationale for an arginine vasopressin (argipressin) infusion was put forward after it was discovered that patients in shock states might have an endogenous arginine vasopressin deficiency. Subsequently, several investigations impressively demonstrated that arginine vasopressin can successfully stabilise haemodynamics even in advanced vasodilatory shock. We report on physiological and pharmacological aspects of arginine vasopressin, and summarise current clinical knowledge on employing a continuous arginine vasopressin infusion in critically ill patients with catecholamine-resistant vasodilatory shock of different aetiologies. In view of presented experimental evidence and current clinical experience, a continuous arginine vasopressin infusion of ∼2 to ∼6 IU/h can be considered as a supplemental strategy to vasopressor catecholamines in order to preserve cardiocirculatory homeostasis in patients with advanced vasodilatory shock. Because data on adverse effects are still limited, arginine vasopressin should be reserved for patients in whom adequate haemodynamic stabilisation cannot be achieved with conventional vasopressor therapy or who have obvious adverse effects of catecholamines that result in further significant haemodynamic deterioration. For the same reasons, arginine vasopressin should not be used as a single, alternative vasopressor agent instead of catecholamine vasopressors. Future prospective studies will be necessary to define the exact role of arginine vasopressin in the therapy of vasodilatory shock.
- 3 October 2002
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 46 (9) , 1161-1164
Cardiac failure and multiple organ dysfunction syndrome in a patient with endocrine adenomatosis
In this case report, we present the successful therapy of severe cardiac failure in pituitary adrenal insufficiency. A previously healthy 56‐year‐old‐man in pituitary coma due to an atypical variant of multiple endocrine adenomatosis (pituitary adenoma and pheochromocytoma) suffered from cardiac failure resistant to catecholamine and standard hydrocortisone therapy. After two bolus injections of dexamethasone (2 × 24 mg) mean arterial pressure and cardiac function dramatically improved, probably due to restoration of permissive effects on catecholamine action and reversal of pathophysiological mechanisms of cardiac failure. We conclude that in patients with severe cardiovascular failure in pituitary coma the administration of potent glucocorticoids may be more effective in reversing cardiovascular failure than standard dosages of hydrocortisone.
- 3 October 2002
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 46 (9) , 1161-1164
Cardiac failure and multiple organ dysfunction syndrome in a patient with endocrine adenomatosis
In this case report, we present the successful therapy of severe cardiac failure in pituitary adrenal insufficiency. A previously healthy 56‐year‐old‐man in pituitary coma due to an atypical variant of multiple endocrine adenomatosis (pituitary adenoma and pheochromocytoma) suffered from cardiac failure resistant to catecholamine and standard hydrocortisone therapy. After two bolus injections of dexamethasone (2 × 24 mg) mean arterial pressure and cardiac function dramatically improved, probably due to restoration of permissive effects on catecholamine action and reversal of pathophysiological mechanisms of cardiac failure. We conclude that in patients with severe cardiovascular failure in pituitary coma the administration of potent glucocorticoids may be more effective in reversing cardiovascular failure than standard dosages of hydrocortisone.
- 30 April 2002
- Published by Springer Nature in Intensive Care Medicine
- Vol. 28 (6) , 746-751
Cardiac performance during vasopressin infusion in postcardiotomy shock
Objective. Arginine-vasopressin (AVP) might be a potent vasopressor agent in catecholamine-resistant postcardiotomy shock. However, its use remains experimental because of considerations about deleterious effects on the heart. We report on the effects of continuous AVP-infusion on cardiac performance, biomarkers of myocardial ischemia, and systemic hemodynamics in catecholamine-resistant postcardiotomy shock. Design. Retrospective study. Setting. Twenty-one-bed general and surgical intensive care unit. Patients. Forty-one patients with catecholamine-resistant postcardiotomy shock. Interventions. Continuous infusion of AVP. Measurements and results. Heart rate (HR), heart rhythm, mean arterial pressure (MAP), central venous pressure, mean pulmonary arterial pressure, cardiac index (CI), stroke volume index (SVI), left ventricular stroke work index (LVSWI), systemic vascular resistance (SVR) as well as milrinone and norepinephrine requirements were collected before and 1, 4, 12, 24, and 48 h after start of AVP infusion. Creatine kinase MB and troponin-I serum concentrations were measured daily. During AVP administration we observed a significant decrease in HR (–14.8%), milrinone (–17.5%), and norepinephrine requirements (–54.9%) as well as biomarkers of cardiac ischemia and a significant increase in LVSWI (+46.2%), MAP (+41.8%) and SVR (+60%). CI and SVI remained unchanged. Forty-five percent of postoperative new-onset tachyarrhythmias (TA) converted into sinus rhythm during AVP infusion. Conclusions. AVP was devoid of adverse effects on the heart in these patients with catecholamine-resistant postcardiotomy shock. The significant reduction in HR, vasopressor, and inotropic support suggest a substantial improvement in myocardial performance. These findings are supported by a significant decrease of cardiac enzymes and cardioversion of TA into sinus rhythm in 45.5% of patients with new-onset TA.
- 30 April 2002
- Published by Springer Nature in Intensive Care Medicine
- Vol. 28 (6) , 746-751
Cardiac performance during vasopressin infusion in postcardiotomy shock
Objective. Arginine-vasopressin (AVP) might be a potent vasopressor agent in catecholamine-resistant postcardiotomy shock. However, its use remains experimental because of considerations about deleterious effects on the heart. We report on the effects of continuous AVP-infusion on cardiac performance, biomarkers of myocardial ischemia, and systemic hemodynamics in catecholamine-resistant postcardiotomy shock. Design. Retrospective study. Setting. Twenty-one-bed general and surgical intensive care unit. Patients. Forty-one patients with catecholamine-resistant postcardiotomy shock. Interventions. Continuous infusion of AVP. Measurements and results. Heart rate (HR), heart rhythm, mean arterial pressure (MAP), central venous pressure, mean pulmonary arterial pressure, cardiac index (CI), stroke volume index (SVI), left ventricular stroke work index (LVSWI), systemic vascular resistance (SVR) as well as milrinone and norepinephrine requirements were collected before and 1, 4, 12, 24, and 48 h after start of AVP infusion. Creatine kinase MB and troponin-I serum concentrations were measured daily. During AVP administration we observed a significant decrease in HR (–14.8%), milrinone (–17.5%), and norepinephrine requirements (–54.9%) as well as biomarkers of cardiac ischemia and a significant increase in LVSWI (+46.2%), MAP (+41.8%) and SVR (+60%). CI and SVI remained unchanged. Forty-five percent of postoperative new-onset tachyarrhythmias (TA) converted into sinus rhythm during AVP infusion. Conclusions. AVP was devoid of adverse effects on the heart in these patients with catecholamine-resistant postcardiotomy shock. The significant reduction in HR, vasopressor, and inotropic support suggest a substantial improvement in myocardial performance. These findings are supported by a significant decrease of cardiac enzymes and cardioversion of TA into sinus rhythm in 45.5% of patients with new-onset TA.
- 1 May 2001
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 45 (5) , 543-549
Risk factors associated with new onset tachyarrhythmias after cardiac surgery – a retrospective analysis
Background: Tachyarrhythmias (TA) represent a frequent and serious problem after cardiac surgery. We retrospectively analyzed 987 cardiac surgery patients admitted to a surgical intensive care unit between 1996 and 1999 to assess incidence and risk factors associated with development of postoperative TA in the intensive care unit. Methods: TA (n=149) were defined as non‐sinus rhythm with a heart rate (HR) ≥100 bpm in patients with preoperative sinus rhythm or as heart rate ≥130 bpm in patients with preoperative atrial fibrillation. A total of 787 patients served as controls (C). Demographic, premorbidity and perioperative data, admission SAPS and MODS‐score, presence of clinical syndromes systemic inflammatory response syndrome (SIRS) and sepsis were univariately compared between groups. For prediction of independent risk factors for TA‐development two multiple logistic regression models were finally established. Results: Concerning TA, atrial fibrillation and flutter (76%) were observed most frequently, followed by paroxysmal supraventricular tachycardia (15%) and ventricular tachycardia/fibrillation (11%). Age, a history or presence of congestive heart failure, development of SIRS and sepsis, severity of multiple organ dysfunction syndrome and in particular severity of cardiovascular failure proved to be independent risk factors for development of TA. Conclusion: In cardiac surgery patients, age, a history or presence of congestive heart failure, postoperative development of a systemic inflammatory response syndrome or sepsis and the severity of multiple organ function syndrome were independent predictors for development of TA in the intensive care unit. The association of severity of cardiovascular dysfunction with TA strongly suggests a causal relationship between catecholamine therapy and TA‐development.
- 1 May 2001
- Published by Wiley in Acta Anaesthesiologica Scandinavica
- Vol. 45 (5) , 543-549
Risk factors associated with new onset tachyarrhythmias after cardiac surgery – a retrospective analysis
Background: Tachyarrhythmias (TA) represent a frequent and serious problem after cardiac surgery. We retrospectively analyzed 987 cardiac surgery patients admitted to a surgical intensive care unit between 1996 and 1999 to assess incidence and risk factors associated with development of postoperative TA in the intensive care unit. Methods: TA (n=149) were defined as non‐sinus rhythm with a heart rate (HR) ≥100 bpm in patients with preoperative sinus rhythm or as heart rate ≥130 bpm in patients with preoperative atrial fibrillation. A total of 787 patients served as controls (C). Demographic, premorbidity and perioperative data, admission SAPS and MODS‐score, presence of clinical syndromes systemic inflammatory response syndrome (SIRS) and sepsis were univariately compared between groups. For prediction of independent risk factors for TA‐development two multiple logistic regression models were finally established. Results: Concerning TA, atrial fibrillation and flutter (76%) were observed most frequently, followed by paroxysmal supraventricular tachycardia (15%) and ventricular tachycardia/fibrillation (11%). Age, a history or presence of congestive heart failure, development of SIRS and sepsis, severity of multiple organ dysfunction syndrome and in particular severity of cardiovascular failure proved to be independent risk factors for development of TA. Conclusion: In cardiac surgery patients, age, a history or presence of congestive heart failure, postoperative development of a systemic inflammatory response syndrome or sepsis and the severity of multiple organ function syndrome were independent predictors for development of TA in the intensive care unit. The association of severity of cardiovascular dysfunction with TA strongly suggests a causal relationship between catecholamine therapy and TA‐development.
- 18 March 2001
- Published by Springer Nature in Intensive Care Medicine
- Vol. 27 (3) , 593-601
Effects of norepinephrine and phenylephrine on intestinal oyxgen supply and mucosal tissue oxygen tension
Objectives: To investigate effects of intravenous norepinephrine (NE) and phenylephrine (PE) on intestinal oxygen supply in an autoperfused, innervated jejunal segment. Design and setting: Prospective, randomized animal study in an animal research laboratory. Materials and methods: In 24 anesthetized and normoventilated pigs a segment of the jejunal mucosa was exposed by midline laparotomy and antimesenteric incision. Mucosal oxygen tension (PO2muc; Clark-type surface oxygen electrodes), microvascular hemoglobin oxygen saturation (HbO2, tissue reflectance spectrophotometry), and microvascular blood flow (perfusion units, PU; laser Doppler velocimetry), systemic hemodynamics, mesenteric-venous acid base and blood gas variables, and systemic acid base and blood gas variables were recorded after a resting period and at 20-min intervals during infusion of NE (0.01, 0.05, 0.1, 0.5, 1, 2 µg×kg–1×min–1; n=8) or PE (0.1, 0.5, 1, 2, 5, 10 µg×kg–1×min–1; n=8) and in controls (n=8) without treatment. Results: NE infusion led to significant tachycardia, an increase in cardiac output, and systemic oxygen delivery and consumption while PE progressively increased mean arterial pressure with only small effects on systemic blood flow. NE or PE infusion did not affect mesenteric venous oxygen tension (baseline: PE 53±5, NE, 52±4.2 mmHg), mesenteric oxygen extraction ratio (baseline: PE 0.29±0.08, NE 0.3±0.06), jejunal microvascular blood flow (baseline: PE 254±127, NE 282±72 PU), PO2muc (baseline: PE 31±9.1, NE 33±11 mmHg), and HbO2 (baseline: PE 52±9.6%, NE 58±11.6%). Conclusion: Despite major differences in systemic hemodynamics jejunal tissue oxygen supply is not affected by progressively increasing intravenous infusion of norepinephrine and phenylephrine.
- 18 March 2001
- Published by Springer Nature in Intensive Care Medicine
- Vol. 27 (3) , 593-601
Effects of norepinephrine and phenylephrine on intestinal oyxgen supply and mucosal tissue oxygen tension
Objectives: To investigate effects of intravenous norepinephrine (NE) and phenylephrine (PE) on intestinal oxygen supply in an autoperfused, innervated jejunal segment. Design and setting: Prospective, randomized animal study in an animal research laboratory. Materials and methods: In 24 anesthetized and normoventilated pigs a segment of the jejunal mucosa was exposed by midline laparotomy and antimesenteric incision. Mucosal oxygen tension (PO2muc; Clark-type surface oxygen electrodes), microvascular hemoglobin oxygen saturation (HbO2, tissue reflectance spectrophotometry), and microvascular blood flow (perfusion units, PU; laser Doppler velocimetry), systemic hemodynamics, mesenteric-venous acid base and blood gas variables, and systemic acid base and blood gas variables were recorded after a resting period and at 20-min intervals during infusion of NE (0.01, 0.05, 0.1, 0.5, 1, 2 µg×kg–1×min–1; n=8) or PE (0.1, 0.5, 1, 2, 5, 10 µg×kg–1×min–1; n=8) and in controls (n=8) without treatment. Results: NE infusion led to significant tachycardia, an increase in cardiac output, and systemic oxygen delivery and consumption while PE progressively increased mean arterial pressure with only small effects on systemic blood flow. NE or PE infusion did not affect mesenteric venous oxygen tension (baseline: PE 53±5, NE, 52±4.2 mmHg), mesenteric oxygen extraction ratio (baseline: PE 0.29±0.08, NE 0.3±0.06), jejunal microvascular blood flow (baseline: PE 254±127, NE 282±72 PU), PO2muc (baseline: PE 31±9.1, NE 33±11 mmHg), and HbO2 (baseline: PE 52±9.6%, NE 58±11.6%). Conclusion: Despite major differences in systemic hemodynamics jejunal tissue oxygen supply is not affected by progressively increasing intravenous infusion of norepinephrine and phenylephrine.
- 22 December 2000
- Vol. 112 (24) , 1049-52
[Multiple organ failure following inhalation of butane gas: a case report].
Most cases of acute poisoning by butane and other volatile compounds occur in young people as a consequence of substance abuse by inhalation. Clinical symptoms are caused by asphyxia and mainly affect the cardiovascular, respiratory and central nervous system. There are also reported deaths from intoxication of butane inhalation, mostly by cardiac arrhythmia. We report the case of a healthy 14 year-old boy who inhaled butane gas from an aerosol can for refilling cigarette lighters. Despite successful resuscitation and defibrillation, he died two days later from multiple organ failure involving the central nervous system, cardiovascular system, pulmonary system and the liver. Although such incidents are rare in middle European countries, emergency and intensive care medicine staff should be instructed on the consequences and management of butane gas poisoning.
- 22 December 2000
- Vol. 112 (24) , 1049-52
[Multiple organ failure following inhalation of butane gas: a case report].
Most cases of acute poisoning by butane and other volatile compounds occur in young people as a consequence of substance abuse by inhalation. Clinical symptoms are caused by asphyxia and mainly affect the cardiovascular, respiratory and central nervous system. There are also reported deaths from intoxication of butane inhalation, mostly by cardiac arrhythmia. We report the case of a healthy 14 year-old boy who inhaled butane gas from an aerosol can for refilling cigarette lighters. Despite successful resuscitation and defibrillation, he died two days later from multiple organ failure involving the central nervous system, cardiovascular system, pulmonary system and the liver. Although such incidents are rare in middle European countries, emergency and intensive care medicine staff should be instructed on the consequences and management of butane gas poisoning.